Asthma Clinical Trials: APAC Dominate Between 2019-2023

Global Data recently released information about asthma clinical trials conducted worldwide, where the Asia-Pacific (APAC) region created a tough spot for the total trial phase conducted. 

Prominently, on the list of countries, China, India, and South Korea rank among the top countries of APAC. GlobalData’s Clinical trials report shows that between 2019 and 2023, over 51.8% of asthma trials were initiated in the APAC region. 

According to this report by GlobalData, China took the lead in asthma clinical trials with over 337 trials, followed by India, which had 137 trials, and South Korea, which booked around 83 trials. These data demonstrate the diverse research landscapes of these countries to measure which section, lower or higher-income-oriented countries, are burdened with the spread of diseases. 

Looking into the matter, Sravani Meka, senior immunology analyst at GlobalData, comments: “These findings appear to be consistent with research, which has shown that while asthma prevalence tends to be lower in low—and low-middle-income countries (LMICs) compared to high-income countries, the unmet need and overall burden of the disease are significantly higher.”

The report states that the APAC region accounts for asthma-related deaths. Precisely, the four phases of these clinical trials demonstrate Phase I trials as 42.4%, Phase II (21.4%), Phase III (10.8%) and Phase IV (16.5%) focusing on research and innovation for asthma treatments. Countries are alarmed to establish robust treatments and strategies to manage the growing demand for early diagnosis, increased access to care, and advanced therapies. The healthcare sector and research & development institutions must adopt more progressive measures to improve the healthcare landscape across the APAC region.